Journal Mobile Options
Table of Contents
Vol. 55, No. 6, 2009
Issue release date: November 2009
Gerontology 2009;55:607–613

Non-Alcoholic Fatty Liver Disease in Older People

Frith J. · Day C.P. · Henderson E. · Burt A.D. · Newton J.L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Non-alcoholic fatty liver disease (NAFLD) is principally a disease of middle and old age. Previous studies reported it to be benign in old age, however more recent studies suggest an increased mortality in the >60-year-olds. Objectives: To define the prevalence of risk factors and the laboratory and histological differences between different age groups with NAFLD, in order to confirm/refute findings in previous smaller studies. Methods: Retrospective, cohort study set in a tertiary liver clinic in the UK. 351 consecutive patients with biopsy-proven NAFLD were divided into an older (≥60), a middle-aged (≥50 to <60) and a younger (<50) group. Blood pressure, body mass index, serum lipids, glucose, HbA1C, albumin, liver enzymes, bilirubin, mean cell volume (MCV), platelets, and insulin resistance were recorded. In addition, liver biopsy was analyzed for steatosis, inflammation and fibrosis. Results: Older patients had significantly more risk factors (hypertension, obesity, diabetes, hyperlipidaemia). Albumin, alanine aminotransferase (ALT), ALT/aspartate aminotransferase ratio and platelets significantly reduced with advancing age. MCV and alkaline phosphatase significantly increased with increasing age. Older patients had significantly greater fibrosis on biopsy with less percentage fat, with the cirrhotic patients being significantly older than non-cirrhotics. Insulin resistance was similar in younger and older groups. Conclusion: NAFLD affects mainly the middle-aged and the elderly. With advancing age come more risk factors for its development. Older patients show more severe biochemical, haematological and histological changes, with cirrhotics having a significantly greater age than those with milder disease.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bellentani S, Saccoccio G, Masutti F, et al: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112–117.
  2. Browning J, Szczepaniak L, Dobbins R, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–1395.
  3. Bedogni G, Miglioli L, Masutti F, et al: Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005;42:44–52.
  4. Skelly M, James P, Ryder S: Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195–199.
  5. Day C: Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006;6:19–25.
  6. Marchesini G, Marzocchi R, Agostini F, et al: Non-alcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421–427.
  7. Rodriguez A, Muller D, Metter E, et al: Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:3568–3572.
  8. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, et al: Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26:856–863.
  9. Angulo P, Keach J, Batts K, et al: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356–1362.
  10. Adams L, Lymp J, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;126:113–121.

    External Resources

  12. Anonymous: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988;148:36–69.
  13. Anonymous: The hypertriglyceridemias: risk and management (erratum appears in Am J Cardiol 1991;68:982). Am J Cardiol 1991;68:1A–42A.
  14. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
  15. Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699.
  16. Miyaaki H, Ichikawa T, Nakao K, et al: Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008;28:519–524.
  17. Kagansky N, Levy S, Keter D, et al: Non-alcoholic fatty liver disease – a common and benign finding in octogenarian patients. Liver Int 2004;24:588–594.
  18. Ford E, Giles W, Dietz W: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.
  19. Bjornsson E, Angulo P: Non-alcoholic fatty liver disease. Scand J Gastroenterol 2007;42:1023–1030.
  20. Shoelson S, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169–2180.
  21. Platt D: Age-Dependent Morphological and Biochemical Studies of the Normal and Injured Rat Liver. Liver and Ageing. Stuttgart, Schattauer, 1977, pp 75–83.
  22. Brouwer A, Horan M, Barelds R, et al: Cellular aging of the reticuloendothelial system. Arch Gerontol Geriatr 1986;5:317–324.
  23. Gilmore I, Burroughs A, Murray-Lyon I, et al: Indications, methods and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437–441.
  24. Ekstedt M, Franzen L, Mathiesen U, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–873.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50